Vir Biotechnology prices $150M public offering of 17.6M shares at $8.50/share

Vir Biotechnology, Inc.

Offering of 17,647,059 shares of common stock at $8.50 per share; over-allotment option for 2,647,058 shares.
Net proceeds estimated at $141.1M, or $162.3M if over-allotment fully exercised.
Underwriters include Goldman Sachs, Leerink Partners, Evercore, Barclays; closing expected Feb 27, 2026.
Proceeds for general corporate purposes; shares sold under existing S-3ASR shelf registration.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vir Biotechnology, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters valued at approximately $141.1 million (effective 2026-02-25).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters
Value: approximately $141.1 million
Effective: 2026-02-25

Exact text from the filing

On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-077416

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.